In this episode of Talk for Him: Ask the Expert series, we explore the rapidly evolving field of nuclear medicine and what it means for men living with prostate cancer.
Targeted radiopharmaceutical therapies are transforming the way prostate cancer is diagnosed and treated. These therapies use radioactive molecules that can seek out prostate cancer cells with precision, helping clinicians both identify disease and deliver treatment directly to cancer cells while minimising damage to healthy tissue. Telix is among the companies helping drive this new era of theranostics, with a growing portfolio of prostate cancer imaging and treatment technologies and multiple clinical trials underway globally.
Hosted by global moderator and cancer survivor Katie Clift, this episode features Simone Leyden AM, Director of Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals. Simone brings extensive experience in cancer advocacy, having previously co-founded NeuroEndocrine Cancer Australia and spent more than 15 years championing patient access to innovative treatments and diagnostics.
Together, they will discuss the growing role of nuclear medicine in prostate cancer care, how clinical trials are shaping the future of treatment, and why patient participation in research is so important to advancing outcomes for men and their families.
For more information and support, please call 1800 22 00 99 or visit prostate.org.au.
HOST
Katie Clift
Director of International Public Relations Agency maybe, Global Moderator, Speaker & Breast Cancer Survivor
Katie Clift is Director of may:be, an international counter-cultural public relations agency. An MBA scholar of Warwick Business School. Katie has worked internationally on both sides of communications – in the media (radio, television & digital journalism) and as a PR, spokesperson, and corporate affairs executive - for both the private and public sectors. She has a decade of experience as a moderator, presenting sessions, interviews and press conferences globally, from the World Economic Forum in Davos to the Union for International Cancer Control’s World Cancer Congress and various in-person and online events. Katie was diagnosed with aggressive breast cancer in her 30s, and after 18 months of active treatment, returned to life and work more determined than ever to advocate for people affected by all types of cancer, and upscale communications for nonprofits globally.
GUEST
Simone Leyden AM, Director, Global Patient Advocacy and Government Affairs, Telix Pharmaceuticals
Simone Leyden AM is Director of Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals, a global biopharmaceutical company focused on targeted radiopharmaceuticals for cancer and rare diseases. She has more than 15 years of experience in health advocacy and public policy and is widely recognised for her work improving access to innovative treatments, diagnostics and clinical trials.
Prior to joining Telix, Simone co-founded NeuroEndocrine Cancer Australia and served as Chief Executive Officer, helping establish one of Australia's leading patient advocacy organisations for rare cancers. Her work has focused on ensuring patients have equitable access to emerging therapies and supporting greater awareness, research investment and policy reform across the healthcare system.
